Catalent, Inc. (CTLT)
NYSE: CTLT · IEX Real-Time Price · USD
56.20
+0.04 (0.07%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Catalent Revenue
Catalent had revenue of $4.14B in the twelve months ending March 31, 2024, down -8.01% year-over-year. Revenue in the quarter ending March 31, 2024 was $1.07B with 3.57% year-over-year growth. In the fiscal year ending June 30, 2023, Catalent had annual revenue of $4.26B, a decrease of -11.22%.
Revenue (ttm)
$4.14B
Revenue Growth
-8.01%
P/S Ratio
2.46
Revenue / Employee
$232,303
Employees
17,800
Market Cap
10.17B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 4.26B | -539.00M | -11.22% |
Jun 30, 2022 | 4.80B | 804.00M | 20.11% |
Jun 30, 2021 | 4.00B | 904.00M | 29.22% |
Jun 30, 2020 | 3.09B | 576.00M | 22.88% |
Jun 30, 2019 | 2.52B | 54.60M | 2.22% |
Jun 30, 2018 | 2.46B | 388.00M | 18.70% |
Jun 30, 2017 | 2.08B | 227.30M | 12.30% |
Jun 30, 2016 | 1.85B | 17.30M | 0.94% |
Jun 30, 2015 | 1.83B | 3.10M | 0.17% |
Jun 30, 2014 | 1.83B | 27.40M | 1.52% |
Jun 30, 2013 | 1.80B | 105.50M | 6.22% |
Jun 30, 2012 | 1.69B | 163.00M | 10.64% |
Jun 30, 2011 | 1.53B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walgreens Boots Alliance | 145.53B |
Universal Health Services | 14.66B |
Smith & Nephew | 5.55B |
Charles River Laboratories International | 4.11B |
AptarGroup | 3.54B |
Teleflex | 3.00B |
Bruker | 3.00B |
Globus Medical | 1.90B |
CTLT News
- 11 days ago - Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty - Benzinga
- 4 weeks ago - Catalent stockholders approve deal with Novo Holdings - Reuters
- 4 weeks ago - Catalent Stockholders Approve Transaction with Novo Holdings - Business Wire
- 4 weeks ago - Surely Wines Appoints Brandon Joldersma as New CEO - Business Wire
- 7 weeks ago - Catalent, Inc. Reports Third Quarter Fiscal 2024 Results - Business Wire
- 7 weeks ago - Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer - GlobeNewsWire
- 2 months ago - FTC Seeks More Information on $16.5 Billion Novo-Catalent Deal - WSJ
- 2 months ago - US FTC seeks more information on Novo Nordisk parent-Catalent deal - Reuters